EFMC Symposium

April 8-11, 2024
Utrecht, The Netherlands

The EFMC | ACSMEDI Medicinal Chemistry Frontiers is co-organised as a collaboration between the EFMC, European Federation for Medicinal chemistry and Chemical biology, and ACS MEDI, the division of Medicinal Chemistry of the American Chemical Society.

The 2024 programme will include:

  • 3 high quality plenary lectures
  • 9 sessions on key topics in Medicinal Chemistry
  • About 18 oral communications selected from the submitted abstracts
  • An extensive social programme to maximise your networking opportunities
  • poster session and a commercial exhibition

EFMC | ACSMEDI Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts, researchers and early career trainees in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, and early toxicology.


  1. New Chemistries for the Preparation of DNA-Encoded Libraries
  2. Targeted Protein Degradation
  3. Recent Advances in Neurodegenerative Diseases
  4. Fragment Based Drug Discovery
  5. Protein-protein Interactions
  6. Emerging Synthetic Methodologies
  7. Targeting Immune Checkpoints with Small Molecules
  8. From RNA Targeting to Degraders and Beyond: Impact of Novel Modalities on Clinical Pipelines


Calendar of Abstract Submissions

  • Deadline for Oral Communication submission and free Poster submission: January 25, 2024
  • Announcement of the accepted oral communications: February 2024
  • After January 25 and until February 22, 2024: abstracts for Posters can still be submitted, but with a handling fee of EUR 50,00

Registration Fees

  • Early-bird registration deadline: January 25, 2024


We look forward meeting you in Utrecht! 

The Organising Committee

EFMC Symposium

April 21-24, 2024
Oegstgeest (near Leiden), The Netherlands

Course Outline:

Technologies for drug discovery are constantly evolving. Significant developments within the last 20 years range from the development of DNA-encoded libraries for hit finding and even hit-to-lead optimisation to the reinvigoration of irreversible inhibitors resulting in innovative oncology drugs such as osimertinib and sotorasib.

This course will cover advanced methods, new technologies and tools available for medicinal chemists, with a focus on oncology drug discovery, including fragment based-drug discovery, DNA-encoded library technologies, covalent drug discovery and small molecules that target RNA. The course will finish with a series of oncology case studies successfully utilising these drug discovery technologies for the development of clinical candidates and marketed drugs.

Course Organisers:

  • Prof. Mike Waring (Newcastle University, United Kingdom)
  • Dr Hannah Stewart (Newcastle University, United Kingdom)

Local Organiser:

  • Prof. Laura Heitman (Leiden University, The Netherlands)

EFMC Sponsored Event

April 25, 2024
Stevenage, United Kingdom

Known colloquially as the “Hatfield MedChem” meeting*, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

To register, please follow this link.